Medivir AB (publ) (MVRBF) Stock Price, News & Analysis

Company Overview

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the company is developing MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors, as well as USP-1/TNG348, USP-7, and MBLI/MET-X, which completed preclinical trials for treating cancer and infection. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.

Key Stats

• Today's Range: $0.82 to $0.82
• 50-Day Range: $0.82 to $0.82
• 52-Week Range: $0.68 to $0.82
• Volume: N/A
• Average Volume: 925 shs
• Market Capitalization: N/A
• P/E Ratio: 0.03
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MVRBF Stock Analysis - Frequently Asked Questions

How have MVRBF shares performed this year?

Medivir AB (publ)'s stock was trading at $0.82 at the start of the year. Since then, MVRBF shares have increased by 0.0% and is now trading at $0.82.
View the best growth stocks for 2025 here.

How do I buy shares of Medivir AB (publ)?

Shares of MVRBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:MVRBF
• CUSIP: N/A
• CIK: N/A
• Web: www.medivir.com
• Phone: (685) 468-3100
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: 0.03
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A